Sarepta Therapeutics, Inc. - SRPT
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 30, 2026 | SCHEDULE 13G | Vanguard Capital Management | 5.11% | 5,369,116 | View |
| Apr 29, 2026 | SCHEDULE 13G | Vanguard Portfolio Management | 6.43% | 6,751,168 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G | AQR Capital Management, LLC | 7.73% | 8,104,869 | View |
| Feb 13, 2026 | SCHEDULE 13G | AQR Capital Management Holdings, LLC | 7.73% | 8,104,869 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 12.6% | 13,232,652 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.